Showing results (201-210 of 220) with videos related to
Sort By:
Pageof 22
The New England Journal of Medicine|December 8, 2015
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C Byrd, Bonnie Harrington, Susan O'Brien, et al.Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent LymphomaNathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid LeukemiaPinkal M Desai, Janice Brown, Saar Gill, et al.The New England Journal of Medicine|December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L Locke, David B Miklos, Caron A Jacobson, et al.Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.Pageof 22